GO:0033829 O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0033829 describes the enzymatic transfer of beta-D-GlcNAc from UDP-GlcNAc to fucose on fucosylated proteins, a key step in Notch glycosylation.
• This activity is mediated by Fringe family glycosyltransferases: Lunatic Fringe (LFNG), Manic Fringe (MFNG), and Radical Fringe (RFNG).
• Fringe-mediated glycosylation modulates Notch receptor activation, influencing cell fate decisions in development and disease.
• Dysregulation of this activity is linked to spondylocostal dysostosis, breast cancer, pancreatic cancer, and prostate cancer.
• LFNG mutations cause skeletal defects, while MFNG and LFNG act as tumor suppressors or oncogenes in a context-dependent manner.
• CRISPR-based models (knockout, point mutation, knock-in, overexpression) enable precise dissection of GO:0033829 in Notch signaling and disease.
Description
O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase activity (GO:0033829) is a molecular function that catalyzes the addition of N-acetylglucosamine (GlcNAc) to fucose residues on specific protein substrates, notably Notch receptors. This glycosylation event is essential for proper Notch signaling, a pathway that controls cell proliferation, differentiation, and apoptosis across metazoans. The enzymes responsible, known as Fringe glycosyltransferases, include Lunatic Fringe (LFNG), Manic Fringe (MFNG), and Radical Fringe (RFNG), which exhibit distinct but overlapping roles in development and disease. Researchers study GO:0033829 to understand how glycosylation fine-tunes Notch activity, and how its dysregulation contributes to congenital disorders and cancer. The term is also critical for interpreting CRISPR screens targeting glycosyltransferases and for designing therapeutic strategies that modulate Notch signaling.
O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase activity At A Glance
| GO ID | GO:0033829 |
|---|---|
| GO term | O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase activity |
| Ontology | molecular_function |
| Synonym | O-fucosylpeptide beta-1,3-N-acetylglucosaminyltransferase activity; UDP-D-GlcNAc:O-L-fucosylpeptide 3-beta-N-acetyl-D-glucosaminyltransferase activity |
| Major function | Transfer of beta-D-GlcNAc from UDP-GlcNAc to fucose on fucosylated proteins, modulating Notch signaling |
| Enzymes | Lunatic Fringe (LFNG), Manic Fringe (MFNG), Radical Fringe (RFNG) |
| Substrates | O-fucosylated proteins, particularly Notch receptors |
| Cofactors | UDP-D-GlcNAc as donor substrate; divalent cations may be required (not specified in QuickGO) |
| Pathological relevance | Spondylocostal dysostosis, breast cancer, pancreatic cancer, prostate cancer |
What Is GO:0033829?
GO:0033829 is defined by QuickGO as the catalysis of the transfer of a beta-D-GlcNAc residue from UDP-D-GlcNAc to the fucose residue of a fucosylated protein acceptor. In simpler terms, it is an enzymatic activity that attaches a sugar molecule (GlcNAc) to another sugar (fucose) that is already attached to a protein. This modification is a key step in the elongation of O-fucose glycans on Notch receptors and other proteins, thereby altering their function and interactions.
Why Is O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase activity Important in Cell Biology?
GO:0033829 is important because it represents a critical enzymatic step that modulates Notch signaling, a pathway central to development and tissue homeostasis. Dysregulation of this activity leads to congenital skeletal disorders and various cancers, making it a target for therapeutic intervention and a key focus in CRISPR-based functional genomics.
• Regulates Notch receptor activation and downstream cell fate decisions.
• Mutations in LFNG cause spondylocostal dysostosis, a congenital vertebral disorder.
• MFNG promotes a claudin-low breast cancer phenotype via Notch-mediated PIK3CG induction.
• LFNG acts as a tumor suppressor in Kras-initiated pancreatic cancer.
• LFNG shows tumor-suppressive activity in prostate cancer through differential Notch modulation.
• MFNG deficiency imposes Jagged1 addiction in intestinal tumor cells.
• LUNATIC FRINGE dominantly modulates NOTCH1 pathway over MANIC or RADICAL FRINGE.
• Bmp9 regulates Notch signaling and angiogenesis via Lunatic Fringe.
• Sequential Notch activation by Fringe regulates ventricular chamber development.
• CRISPR screens targeting glycosyltransferases can identify novel regulators of Notch signaling.
Molecular Mechanism of O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase activity
Substrate Recognition and Binding
In simple terms: The enzyme first grabs onto its target protein and the sugar it will transfer.
The Fringe enzymes (LFNG, MFNG, RFNG) recognize O-fucosylated proteins, primarily Notch receptors, through specific protein-protein interactions. The donor substrate UDP-D-GlcNAc binds to the enzyme's active site, positioning the GlcNAc moiety for transfer to the fucose residue on the acceptor protein.
Catalytic Transfer of GlcNAc
In simple terms: The enzyme then attaches the sugar molecule to the fucose on the target protein.
The catalytic mechanism involves the transfer of beta-D-GlcNAc from UDP-D-GlcNAc to the O-fucose residue on the acceptor protein, forming a beta-1,3 linkage. This glycosylation event is essential for the subsequent elongation of the glycan chain and for modulating Notch receptor function.
Modulation of Notch Signaling
In simple terms: This sugar addition changes how Notch receptors respond to their signals.
Fringe-mediated glycosylation alters Notch receptor affinity for ligands (Delta and Jagged), thereby influencing Notch activation. LFNG, MFNG, and RFNG exhibit distinct effects on Notch signaling, with LFNG showing dominant modulation of NOTCH1. This regulation is critical for cell fate decisions during development and tissue homeostasis.
Regulation of Enzyme Activity
In simple terms: The activity of these enzymes can be turned up or down by other cellular signals.
The expression and activity of Fringe enzymes are regulated at transcriptional and post-transcriptional levels. For example, Bmp9 regulates Notch signaling and angiogenesis via Lunatic Fringe. Additionally, the relative abundance of different Fringe enzymes can determine the outcome of Notch signaling in a context-dependent manner.
Key Genes Involved in GO:0033829 O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase activity
The following genes encode enzymes or proteins directly involved in O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase activity or its regulation.
| Gene | Major Role | Research Relevance |
|---|---|---|
| LFNG | Lunatic Fringe glycosyltransferase; catalyzes GlcNAc transfer to O-fucose on Notch | Mutations cause spondylocostal dysostosis; tumor suppressor in pancreatic and prostate cancer |
| MFNG | Manic Fringe glycosyltransferase; modulates Notch signaling | Promotes claudin-low breast cancer; deficiency imposes Jagged1 addiction in intestinal tumors |
| RFNG | Radical Fringe glycosyltransferase; modulates Notch signaling | Less dominant than LFNG in NOTCH1 modulation |
| NOTCH1 | Notch receptor; substrate for Fringe-mediated glycosylation | Key target of Fringe activity; regulates cell fate and cancer |
| NOTCH2 | Notch receptor; substrate for Fringe-mediated glycosylation | Modulated by Fringe enzymes in various contexts |
| NOTCH3 | Notch receptor; substrate for Fringe-mediated glycosylation | Involved in ventricular chamber development |
| JAG1 | Notch ligand Jagged1; binding affected by Fringe glycosylation | MFNG deficiency imposes Jagged1 addiction in intestinal tumor cells |
| DLL1 | Notch ligand Delta-like 1; binding affected by Fringe glycosylation | Modulated by Fringe enzymes in Notch signaling |
| DLL4 | Notch ligand Delta-like 4; binding affected by Fringe glycosylation | Regulated by Bmp9 via Lunatic Fringe in angiogenesis |
| PIK3CG | Phosphoinositide 3-kinase gamma; induced by MFNG-Notch signaling | Promotes claudin-low breast cancer phenotype |
| BMP9 | Bone morphogenetic protein 9; regulates Notch signaling via Lunatic Fringe | Controls angiogenesis temporal dynamics |
| KRAS | Kirsten rat sarcoma viral oncogene; initiates pancreatic cancer | LFNG acts as tumor suppressor in Kras-initiated pancreatic cancer |
| POFUT1 | Protein O-fucosyltransferase 1; adds fucose to Notch | Creates substrate for Fringe enzymes |
| GXYLT1 | Glucoside xylosyltransferase 1; elongates O-fucose glycans | May cooperate with Fringe in Notch glycosylation |
| XXYLT1 | Xyloside xylosyltransferase 1; elongates O-fucose glycans | May cooperate with Fringe in Notch glycosylation |
| POGLUT1 | Protein O-glucosyltransferase 1; modifies Notch EGF repeats | Affects Notch signaling in concert with Fringe |
How Is O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase activity Regulated?
The activity of O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase is regulated at multiple levels. Transcriptionally, the expression of LFNG, MFNG, and RFNG is controlled by developmental cues and signaling pathways such as BMP9, which regulates Notch signaling and angiogenesis via Lunatic Fringe. Post-translationally, the enzymes may be modified or localized to specific cellular compartments. Additionally, the relative levels of different Fringe enzymes can determine the outcome of Notch signaling, with LFNG showing dominant modulation of NOTCH1 over MFNG and RFNG. In cancer, the activity is often dysregulated, contributing to tumor progression or suppression depending on context.
O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| LFNG | Spondylocostal dysostosis | Knockout mouse, patient-derived iPSCs |
| MFNG | Claudin-low breast cancer | Xenograft models, CRISPR knockout in breast cancer cell lines |
| LFNG | Pancreatic cancer (Kras-initiated) | Conditional knockout in KrasG12D mouse model |
| LFNG | Prostate cancer | Prostate-specific knockout, overexpression in cell lines |
| MFNG | Intestinal tumors (Jagged1 addiction) | Intestinal organoids, CRISPR knockout |
Spondylocostal Dysostosis
Mutations in LFNG, which encodes a key enzyme for GO:0033829, cause spondylocostal dysostosis, a congenital disorder characterized by vertebral and rib abnormalities. This highlights the critical role of O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase activity in skeletal development.
Breast Cancer
MFNG promotes a claudin-low breast cancer phenotype through Notch-mediated induction of PIK3CG. This suggests that dysregulated Fringe activity contributes to aggressive breast cancer subtypes.
Pancreatic and Prostate Cancer
LFNG acts as a potent tumor suppressor in Kras-initiated pancreatic cancer and exhibits tumor-suppressive activity in prostate cancer through differential modulation of Notch receptor activation. These findings underscore the context-dependent roles of GO:0033829 in cancer.
Intestinal Tumors
MFNG deficiency imposes Jagged1 addiction to intestinal tumor cells, linking Fringe-mediated glycosylation to Notch ligand dependency in colorectal cancer.
From O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of LFNG affect Notch signaling in development? | LFNG knockout mouse or zebrafish |
| How does MFNG overexpression contribute to breast cancer? | MFNG overexpression in breast cancer cell lines |
| What is the effect of a specific LFNG point mutation on enzyme activity? | Point mutation knock-in via CRISPR in cell lines |
| Can tagged LFNG be used to track its localization? | Knock-in of fluorescent tag (e.g., GFP) at LFNG locus |
| Which genes interact with Fringe enzymes in Notch signaling? | CRISPR library screening in Notch reporter cells |
| Does RFNG compensate for LFNG loss? | Double knockout of LFNG and RFNG in mice |
How to Study the O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR-Cas9 knockout | Loss of gene function | Study tumor suppressor roles of LFNG |
| RNA-seq | Transcriptional changes | Identify downstream targets of MFNG in breast cancer |
| Proteomics | Protein expression and modifications | Detect glycosylation changes on Notch |
| Glycomics | Glycan structures | Characterize O-fucose glycans modified by Fringe |
| Notch reporter assay | Notch signaling activity | Compare LFNG, MFNG, RFNG effects |
| Immunofluorescence | Protein localization | Visualize Fringe enzymes in cells |
| CRISPR library screening | Gene function at scale | Identify modifiers of Notch signaling |
| Organoid culture | Tissue-like behavior | Model intestinal tumor response to MFNG loss |
CRISPR-Cas9 Knockout
Knockout of LFNG, MFNG, or RFNG using CRISPR-Cas9 allows researchers to study the loss-of-function effects on Notch signaling and cellular phenotypes. This method is particularly useful for validating tumor suppressor or oncogenic roles in cancer models.
RNA Sequencing (RNA-seq)
RNA-seq can measure transcriptional changes in response to modulation of GO:0033829, revealing downstream targets and pathways affected by Fringe activity.
Proteomics and Glycomics
Mass spectrometry-based proteomics and glycomics can identify specific glycosylation changes on Notch receptors and other proteins resulting from Fringe activity.
Notch Reporter Assays
Luciferase-based Notch reporter assays are used to quantify Notch signaling activity following genetic manipulation of Fringe enzymes.
How CRISPR Can Be Used to Study GO:0033829 O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase activity
Knockout
CRISPR knockout of LFNG, MFNG, or RFNG is used to abolish enzyme activity and study its role in Notch signaling. For example, LFNG knockout in pancreatic cancer models confirmed its tumor suppressor function. MFNG knockout in intestinal tumor cells revealed Jagged1 addiction.
Point Mutation
Introducing specific point mutations in LFNG (e.g., those found in spondylocostal dysostosis) via CRISPR allows researchers to dissect the functional impact of individual amino acid changes on enzyme activity and Notch modulation.
Knock-in
Knock-in of epitope tags (e.g., FLAG, GFP) at the endogenous LFNG locus enables tracking of protein expression, localization, and interactions without overexpression artifacts.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression of MFNG or LFNG can model gain-of-function states observed in cancers, such as MFNG-driven breast cancer.
How EDITGENE Supports O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase activity Research
Researchers studying O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase activity-related genes often need to determine whether a candidate gene is causally involved in Notch signaling, development, or cancer. EDITGENE provides comprehensive CRISPR-based services to accelerate this research.
Contact EDITGENE today to design your custom CRISPR model for O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase activity research.
Frequently Asked Questions About O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase activity
What is O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase activity?
It is an enzymatic activity (GO:0033829) that transfers GlcNAc to fucose on proteins, modulating Notch signaling.
What genes are involved in O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase activity?
The main genes are LFNG, MFNG, and RFNG, which encode Fringe glycosyltransferases.
How does GO:0033829 relate to Notch signaling?
Fringe-mediated glycosylation alters Notch receptor affinity for ligands, thereby regulating Notch activation.
What diseases are associated with mutations in LFNG?
LFNG mutations cause spondylocostal dysostosis, a congenital skeletal disorder.
Is MFNG involved in cancer?
Yes, MFNG promotes claudin-low breast cancer through Notch-mediated PIK3CG induction.
What is the role of LFNG in pancreatic cancer?
LFNG acts as a tumor suppressor in Kras-initiated pancreatic cancer.
How can I study GO:0033829 using CRISPR?
CRISPR knockout, point mutation, knock-in, and overexpression models can be used to dissect gene function.
What methods measure Fringe enzyme activity?
Notch reporter assays, glycomics, and proteomics are commonly used.
Which Fringe enzyme is dominant in NOTCH1 modulation?
LUNATIC FRINGE (LFNG) is dominant over MANIC and RADICAL FRINGE.
What experimental models are available for studying Fringe genes?
Knockout mice, cell lines, organoids, and CRISPR-engineered models are widely used.
Conclusion
O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase activity (GO:0033829) is a pivotal enzymatic function that modulates Notch signaling through glycosylation. Its dysregulation is implicated in skeletal disorders and multiple cancers, making it a compelling target for basic and translational research. CRISPR-based models and EDITGENE services provide powerful tools to dissect its mechanisms and therapeutic potential.
References
- 1. Otomo N et al.. 2019. Identification of novel LFNG mutations in spondylocostal dysostosis.. J Hum Genet 64(3):261-264 PMID: 30531807
- 2. Ristori T et al.. 2026. Bmp9 regulates Notch signaling and the temporal dynamics of angiogenesis via Lunatic Fringe.. Dev Cell 61(4):837-853.e9 PMID: 41650956
- 3. Zhang S et al.. 2015. Manic fringe promotes a claudin-low breast cancer phenotype through notch-mediated PIK3CG induction.. Cancer Res 75(10):1936-43 PMID: 25808869
- 4. Zhang S et al.. 2016. Lunatic Fringe is a potent tumor suppressor in Kras-initiated pancreatic cancer.. Oncogene 35(19):2485-95 PMID: 26279302
- 5. Zhang S et al.. 2014. Tumor-suppressive activity of Lunatic Fringe in prostate through differential modulation of Notch receptor activation.. Neoplasia 16(2):158-67 PMID: 24709423
- 6. D'Amato G et al.. 2016. Sequential Notch activation regulates ventricular chamber development.. Nat Cell Biol 18(1):7-20 PMID: 26641715
- 7. Pennarubia F et al.. 2021. Modulation of the NOTCH1 Pathway by LUNATIC FRINGE Is Dominant over That of MANIC or RADICAL FRINGE.. Molecules 26(19) PMID: 34641486
- 8. López-Arribillaga E et al.. 2018. Manic Fringe deficiency imposes Jagged1 addiction to intestinal tumor cells.. Nat Commun 9(1):2992 PMID: 30065304
